RE:RE:RE:RE:RE:RE:RE:articleJust to put TST ' value in context, when a small biotech is taken over by a giant pharma just before or right after the FDA approval, it is usually for a price over 3, 4 or 5 times the peak sales revenue (by the way it won't take 10 years for MCNA to reach peak sales...I strongly disagree with Doug Loe estimate on this).
I'm not suggesting this is how TST is going to be valued in the first weeks after an FDA approval. I know they are listed on TSX and will remain severely undervalued. But I would guess that a market cap of 400M CAN $ is realistic (that's only 280M U$) in march.
But once we get listed on Nasdaq, then I see a rapid increase of the market cap...immediately over 450M U$. US big players know off-label sales will be huge. Whatever approved label TST gets from the FDA won't change the fact that true peak sales will remain around 400M U$. Meaning a long-term MC way over the Billion U$.
Regarding the most probable way of approval, I've talked about it enough (label for CIS-containing disease patients at the minimum). Read the FDA briefing document (page 45) and you will see why.
M80